hydrocortisone-17-butyrate-21-propionate has been researched along with hydrocortisone-17-butyrate* in 6 studies
1 trial(s) available for hydrocortisone-17-butyrate-21-propionate and hydrocortisone-17-butyrate
Article | Year |
---|---|
[Systemic effects of topically applied hydrocortisone 17-butyrate 21-propionate ointment--comparative studies with betamethasone 17-valerate and hydrocortisone 17-butyrate ointment (author's transl)].
Topics: Adolescent; Adult; Aged; Betamethasone; Betamethasone Valerate; Blood Glucose; Child; Clinical Trials as Topic; Double-Blind Method; Eosinophils; Female; Humans; Hydrocortisone; Leukocyte Count; Male; Middle Aged; Ointment Bases | 1982 |
5 other study(ies) available for hydrocortisone-17-butyrate-21-propionate and hydrocortisone-17-butyrate
Article | Year |
---|---|
[Studies on toxicity of hydrocortisone 17-butyrate 21-propionate -1. Acute toxicity of hydrocortisone 17-butyrate 21-propionate and its analogues in mice, rats and dogs (author's transl)].
The acute toxicity of hydrocortisone 17-butyrate 21-propionate (HBP), hydrocortisone 17-butyrate (HB17) and hydrocortisone 21-butyrate (HB21) were investigated by three administration routes (s.c., i. p. and p. o.) in mice, rats and dogs. In the case of HBP, LD50 by oral administration was the highest, and followed by subcutaneous and intraperitoneal administration in mice and rats. And LD50 of HB17 and HB21 were not different from HBP in mice by subcutaneous administration. The depression of spontaneous movement and respiratory rate, ptosis, larcrymation and the collapse were commonly observed in all drugs, and it was independent of administration routes. The autopsy revealed the atrophy of thymus, spleen and adrenal glands, the supprative nodules of heart and liver and the ulcers of alimentary tract in mice and rats. But the changes observed in mice and rats were recognized when 1000 mg/kg of HBP was administered to dogs subcutaneously. Many of these changes were common to glucocorticoids, and the LD50 of HBP was rather high compared with other synthetic steroids; therefore, HBP was among less toxic steroid. Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Dogs; Female; Hydrocortisone; Injections, Intraperitoneal; Injections, Subcutaneous; Lethal Dose 50; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred Strains | 1981 |
[Studies on toxicity of hydrocortisone 17-butyrate 21-propionate -6. Subacute toxicity in dogs by percutaneous administration (author's transl)].
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Betamethasone Valerate; Blood; Blood Chemical Analysis; Body Weight; Dogs; Eating; Female; Hydrocortisone; Male; Organ Size; Skin | 1981 |
[Studies on toxicity of hydrocortisone 17-butyrate 21-propionate -2. Subacute toxicity in rats by subcutaneous administration (author's transl)].
Subacute toxicity of hydrocortisone 17-butyrate 21-propionate (HBP), a new synthetic corticosteroid, was studied in rats, using betamethasone 17-valerate (BV) and hydrocortisone 17-butyrate (HB) as the reference drugs. HBP was subcutaneously injected to rats at the daily doses of 0.08, 0.4, 2.0, 10 and 50 mg/kg for 30 days. BV and HB were also administered at the daily doses of 0.08, 0.4 and 2.0 mg/kg. The recovery test was performed for 4 weeks after administration of HBP, BV and HB. The suppression of body weight gain by HBP was observed at the doses more than 0.08 mg/kg in male and more than 2.0 mg/kg in female rats. In addition, at the doses more than 0.4 mg/kg of HBP induced the dose-dependent symptoms such as decrease in the number of circulating white blood cells, lymphocyte counts and S-ALP level, increase in total cholesterol, GOT and GPT level of serum, and regressive changes in adrenals, lymphatic and hematopoietic tissues. There were fatal cases in rats given 50 mg/kg of HBP. These changes are considered to be common phenomena to other corticosteroids, and less toxic in female than male rats. Changes of symptoms caused by the administration of HBP 2.0 mg/kg were almost recovered after withdrawal. The toxicities of three corticosteroids were in the order of BV greater than HB greater than or equal to HBP in strength. As the result, maximum non-toxic dose of HBP was estimated to be 0.08 mg/kg in female and lower than that in male rats. Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Betamethasone Valerate; Blood; Blood Chemical Analysis; Body Weight; Drinking; Eating; Female; Hydrocortisone; Injections, Subcutaneous; Male; Organ Size; Rats; Rats, Inbred Strains; Sex Factors | 1981 |
[Studies on antigenicity, phototoxicity and other specific toxicities of hydrocortisone 17-butyrate 21-propionate (HBP) (author's transl)].
The present experiments were undertaken to determine the antigenicity and other toxicities of HBP; such as phototoxicity, photosensitivity, ulcerogenicity, adrogenic-myotropic, estrogenic and progestational activities, and mutagenicity. No antibody formation and delayed type skin reaction of HBP were seen in rabbits. Active systemic anaphylaxis was not observed in guinea pigs challenged by HBP. In the phototoxicity and photosensitivity test, 0.1% HBP ointment, 0.1% HBP cream and 10% HBP acetone solution did not show any skin reaction with or without irradiation of ultraviolet light. Repeated subcutaneous administration of HBP irritated the gastric and intestinal mucosa dose dependently in rats as hydrocortisone 17-butyrate and betamethasone 17-valerate (BV). HBP had neither androgenic-myotropic nor estrogenic activity, but antiestrogenic activity was observed. The progestational activity of HBP in immature rabbit pretreated with estrone was less potent than BV. In the mutagenicity test os HBP investigated by the reverse mutation according to the method by Ames, no significant increase in the number of revertants was observed in the presence or absence of S9 mixture. Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Antibody Formation; Antigens; Betamethasone Valerate; Digestive System; Drug Hypersensitivity; Female; Genitalia, Male; Guinea Pigs; Hydrocortisone; Male; Mice; Mice, Inbred ICR; Mutagens; Photosensitivity Disorders; Rabbits; Rats; Rats, Inbred Strains; Skin; Uterus | 1981 |
[Studies of toxicity of hydrocortisone 17-butyrate 21-propionate -5. Chronic toxicity in rats by percutaneous administration (author's transl)].
Chronic toxicity of a new synthetic corticosteroid, hydrocortisone 17-butyrate 21-propionate (HBP), was investigated in rats of both sexes. HBP was percutaneously given to rats with 0.1%, 0.5% cream and ointment at the daily dose level of 150 mg per 100 g body weight for 6 months. For the comparison, the percutaneous toxicity with 0.12% betamethasone 17-valerate (BV) cream and ointment, and 0.1% hydrocortisone 17-butyrate (HB) cream and ointment at the daily dose level of 150 mg per 100 g body weight were studied. Rats receiving HBP showed the dose-dependent changes such as the suppression of body weight gain and food intake, emaciation, decrease in the number of white blood cells and lymphocytes, total protein, increase in the number of red cells, hematocrit, hemoglobin, blood sugar and total cholesterol, regressive changes in adrenal cortex, lymphatic and hematopoietic tissues and skin, and gastric erosion, which have been well known as toxic effects of synthetic corticosteroids. These findings were comparatively high toxic in male, and almost disappeared in rats elapsed recovery time of month after withdrawal of HBP. The toxicities of HBP, BV and HB were qualitatively same. However, the grade of effects of HBP toxicity was similar to that of HB, weaker than of BV. Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Betamethasone Valerate; Blood; Blood Chemical Analysis; Body Weight; Drinking; Eating; Female; Hydrocortisone; Male; Organ Size; Rats; Rats, Inbred Strains; Skin | 1981 |